The Critical Path Institute Adopts the Rosetta Resolver® System for the Predictive Safety Testing Consortium

SEATTLE, Wash., and TUCSON, Ariz., March 19, 2007– Rosetta Biosoftware announced today that The Critical Path Institute (C-Path) adopted the Rosetta Resolver® system for C-Path’s Predictive Safety Testing Consortium. The Consortium brings together major pharmaceutical companies to work in collaboration with C-Path and the U.S. Food and Drug Administration (FDA). The Consortium's objective is to enable the exchange of knowledge and resources to improve drug safety. The Resolver system will be used by the Consortium as a central data management and analysis system as it develops standards for the qualification of tests to evaluate the safety and toxicity of drugs submitted for FDA approval.

The Consortium was established by C-Path and currently has 16 members: Abbott Laboratories, Amgen, Inc., AstraZeneca Pharmaceuticals, L.P., Boehringer-Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline, Iconix Biosciences, Inc., Johnson & Johnson Pharmaceutical Research & Development, LLC, Merck & Co., Inc., Genomics Institute of the Novartis Research Foundation, Pfizer Global Research & Development, Roche Palo Alto Pharmaceuticals, sanofi-aventis U.S. Inc., Schering Plough Research Institute, and Wyeth Pharmaceuticals, Inc. Scientists from the FDA and its European counterpart, the European Agency for the Evaluation of Medicinal Products (EMEA), also participate as advisors.

C-Path is a publicly funded nonprofit research and education institute, which serves to create and support collaborations among industry, academic, and governmental scientists that advance the FDA’s Critical Path Initiative. This initiative is an FDA endeavor to help modernize the process for the development of medical products, including drugs, diagnostics and medical devices.

"In collaboration with the FDA, we are making a rigorous effort to apply new knowledge and scientific expertise to improve the drug development process," said William B. Mattes, Ph.D., director of C-Path’s Predictive Safety Testing Consortium. "The Resolver system has already played an important role in analyzing and maintaining gene expression data for the FDA's Voluntary Genomics Data Submission program. Based on the reputation and performance of the Resolver system, the Consortium determined that it will be a valuable tool for managing the toxicity and safety biomarker data of the Consortium."

“It is an honor for the Resolver system to be chosen by The Critical Path Institute’s Predictive Safety Testing Consortium to support this international effort," said Yelena Shevelenko, vice president and general manger of Rosetta Biosoftware. "The use of the Resolver system by members of the Consortium will provide us with additional input to drive the direction of our product and stimulate continuous enhancements to address the needs of our customers.”

About the Critical Path Institute

Based in Tucson, Arizona with offices in Rockville, MD, The Critical Path Institute (C-Path) was established in 2005 as an independent nonprofit research and education institute to serve as a “trusted third party” for collaborations among scientists from government, industry and academia. C-Path’s vision is to help implement the FDA’s Critical Path Initiative by developing faster, safer and smarter pathways to new medical products. For more information, visit www.C-Path.org.

About the Rosetta Resolver System

The Rosetta Resolver system is a high-capacity data storage, retrieval, and analysis solution for gene expression data. The system is designed for life science research organizations that need to assess compound specificity or toxicity, identify new genes or therapeutic targets, or compare and analyze large databases of expression profiles. Life science research organizations that have licensed the Rosetta Resolver system include many of the top pharmaceutical companies in the world, such as Bristol-Myers Squibb, GlaxoSmithKline, Merck & Co., Inc., and sanofi-aventis, as well as premier academic institutions such as the Harvard University Center for Genomics Research and the California Institute of Technology. Additional information about the Rosetta Resolver system can be found on the Rosetta Biosoftware Web site at www.rosettabio.com.

About Rosetta Biosoftware

Rosetta Biosoftware develops informatics solutions for life science research. Its comprehensive software, including the Rosetta Resolver and Rosetta Elucidator systems, are intended to provide life scientists with advanced, scalable, and easy-to-use analysis platforms and accelerate discovery research. Rosetta Biosoftware is a business unit of Rosetta Inpharmatics LLC, a wholly owned subsidiary of Merck & Co., Inc. (NYSE: MRK). More information about Rosetta Biosoftware is available at www.rosettabio.com.

Forward-Looking Statements

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Neither Rosetta Inpharmatics nor Merck & Co., Inc. undertakes any obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect the business of Merck & Co., Inc. including, among others, the extent to which Rosetta Inpharmatics' technology platform can be used in drug discovery programs, uncertainty of market acceptance of Rosetta Inpharmatics' technologies, ability to compete against existing technologies, and those mentioned in the cautionary statements in Item 1 of Merck’s Form 10-K for the year ended Dec. 31, 2006, and in its periodic reports on Form 10-Q and Form 8-K (if any) which are incorporated by reference.

Rosetta Resolver and Elucidator are U.S. registered trademarks of Rosetta Inpharmatics LLC.

Editorial Contact:
For Rosetta Biosoftware:
Sasha Paegle
+1.206.926.1292

For The Critical Path Institute:
Maura Grogan
+1.520.547.3449